Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 47Neutropenia 26Lymphoma 25Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Neoplasms 11Sarcoma 9Lymphoma, Follicular 9Ovarian Neoplasms 8Lymphoma, Mantle-Cell 8Leukemia 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Chemotherapy-induced Neutropenia 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Testicular Neoplasms 3Sarcoma, Synovial 3Prostatic Neoplasms 3Neurofibrosarcoma 3

Interventions

Cisplatin 45Radiotherapy 32Fluorouracil 27Paclitaxel 26Irinotecan 17Docetaxel 16Oxaliplatin 11Carboplatin 10pembrolizumab 9Cetuximab 8tislelizumab 7Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Radiation 6Leucovorin 6sintilimab 5Nivolumab 5Immunohistochemistry 5Chemotherapy, Adjuvant 5Capecitabine 5nedaplatin 3durvalumab 3camrelizumab 3S 1 (combination) 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Squamous Cell Carcinoma × pegfilgrastim × Clear all
NCT00069953 2017-02-17

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Radiation Therapy Oncology Group

Phase 2 Completed
43 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡